Re: Intro to revised R21 Maryellen O'Brien 28 Jun 2006 11:40 EST
We've got applications rejected by NIH for both the R21 and R03 because of the 1 page limit on Introductions. It is true that the application kit and instructions state a 3 page limit, but the NIH system is only accepting one page. The Help desk told our PI 1 page and it was finally accepted, in both our submissions, when we reduced the Introduction to one page. Maryellen O'Brien Assistant Director Office of Research and Sponsored Programs Rutgers, The State University ASB III, 3 Rutgers Plaza New Brunswick, NJ 08901 Voice: 732-932-0150 x2111 Fax: 732-932-0162 email: xxxxxx@orsp.rutgers.edu web: http://orsp.rutgers.edu -----Original Message----- From: Research Administration List [mailto:xxxxxx@hrinet.org] On Behalf Of Regeane Villarson Sent: Wednesday, June 28, 2006 12:33 PM To: xxxxxx@hrinet.org Subject: Re: [RESADM-L] Intro to revised R21 Another issue for the revised R21: We just submitted a revised R21 and it bounced back with an error stating that the introduction can not be more than 1 PAGE. This is incorrect. As far as I know, the PI still has 3 pages for their intro. The SF 424 R&R Application Guide also confirms the three page limit (page I-18). I sent an e-mail to the help desk regarding this issue. Has any one else received this error? Best, Regeane Villarson, MBA Assistant Manager Office of Research and Sponsored Programs New Jersey Medical School 973-972-8649 972-972-3585 (fax) >>> xxxxxx@LHS.ORG 06/28/06 12:03 PM >>> We have an investigator resubmitting an R21 for July 1 who has raised an interesting question regarding the Introduction in the SF424RR. She and others in the past have typically referenced page numbers in the Research Plan to note some changes or revisions. Since page numbers are now not allowed, any suggestions as to how to handle this? Thanks in advance. The collective talent and wisdom on this LISTSERV is greatly appreciated. Regards, Steve Hunter Legacy Research Portland, Oregon IMPORTANT NOTICE: This communication, including any attachment, contains information that may be confidential or privileged, and is intended solely for the entity or individual to whom it is addressed. If you are not the intended recipient, you should contact the sender and delete the message. Any unauthorized disclosure, copying, or distribution of this message is strictly prohibited. Nothing in this email, including any attachment, is intended to be a legally binding signature. ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.hrinet.org (click on "Listserv Lists") ====================================================================== ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.hrinet.org (click on "Listserv Lists") ====================================================================== ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.hrinet.org (click on "Listserv Lists") ======================================================================